Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome
about
Antiplatelet resistance in strokeImpact of proton pump inhibitors on efficacy of clopidogrel: Review of evidenceClopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designsClopidogrel and proton pump inhibitors--where do we stand in 2012?Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyData management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review.Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in KoreaMultivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databasesPrivacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.Adverse effects of long-term proton pump inhibitor therapy.Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypesPlatelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease.Clinical evidence of interaction between clopidogrel and proton pump inhibitorsPrognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding.Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.Antiplatelet agents and proton pump inhibitors - personalizing treatment.Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing?Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative reviewRisk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settingsIncreased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitorProton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?Antiplatelet therapy in acute coronary syndromes.Clopidogrel and proton pump inhibitors: a clinically meaningful interaction?Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.Clopidogrel pharmacogenetics: metabolism and drug interactions.Variability of clopidogrel response in patients with type 2 diabetes mellitus.Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke.Long-term acid inhibition: benefits and harms.Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?CYP-mediated pharmacologic interference with optimal platelet inhibition.Proton pump inhibitors and clopidogrel: an association to avoid?Clinical relevance of clopidogrel-proton pump inhibitors interaction.
P2860
Q22305927-B23E6610-E0B8-461B-BBFD-520EA32DC1D6Q24608981-D2FB0760-F4EB-4CFA-B9A5-07A12609E115Q24633087-136AB7FB-FD16-4734-80FB-D5281BBE3696Q26825728-FA8679DD-950A-4E5A-A975-83DC7E452A61Q26998331-00DD0ACB-941C-4D82-BA96-507233A38F88Q30980437-154CCCFE-80A5-4D5A-82F3-FFC9177CAC72Q33445961-08618747-A197-424A-8C39-18C4C5D91E08Q33763929-749F1E0E-D20E-4F78-A230-ABBC04599A48Q33853179-8419F046-563E-4672-8725-F46FF55D1868Q34039973-93127BF7-2E8D-4ECB-ACB3-BC899668A5FDQ34104550-9774CDE6-0EB1-449A-A898-393D5C0E777CQ34167899-6716EC3D-3704-4337-9AAF-8F51173991F1Q34174915-BF46FE3C-E11E-410E-9C79-58836EC99908Q34562342-A0B75759-E3BA-4202-AFE6-47612DA2866DQ35033722-FFC170B3-0447-484B-A7A9-61E0F9F942EBQ35147463-905FC18E-59E8-405F-905F-B5B31172D5F7Q36117874-45F7B856-BB37-4FCA-8E31-DBFCAEE8ADCFQ36240776-5737CF74-CA13-41FA-94EA-9055D2D4C65FQ36254177-738B9536-A95F-4521-8E32-1F4B0EE49107Q36390258-84655B86-25EE-426D-A06A-8308DF34D59EQ36441481-E42BD32C-89A2-4A2F-9383-F379D88166B3Q36458864-51EFEB79-33B3-47F0-9CEF-A439F7866D70Q36468237-4CB50FA9-B534-42E3-936E-AF1402AFDB62Q36493369-3A5ED92A-D9F9-40F9-B107-D8594FF7C97CQ36754362-D2457C27-8B80-45CD-9691-83263A0E5448Q37242205-C33678BB-00BC-47C0-9852-86ACB4501FA4Q37310447-4D302ABF-B27C-42BD-907A-4EBF25F19088Q37452994-447BE325-BA52-421F-BA96-82677556D778Q37704535-748892E0-0E3D-494A-94DD-5697B32D8454Q37798110-D1D967CB-9842-469D-A9B8-5EA04C876905Q37831269-A0B75C12-AEFC-40F4-B98F-4369ACF41772Q37837981-DC8E0091-9BFE-45CB-A570-A9FF59773D39Q37912178-A852CDB1-1372-48FB-B3E0-36F4D38DE224Q37936014-07B41354-57B2-4963-8844-0B58A320113CQ37943864-ED25F437-C624-4D53-A2D6-2F8C16ACD8A1Q37957704-49DE65B1-F2C5-45E4-A173-22FCF3C51315Q37973457-626632F3-E33B-4E02-B04E-8A189B137ED0Q38073672-67E08901-E7F7-4D0F-A36B-28C0B5D28DBDQ38136990-B0F58A20-726F-4390-8637-9C41B32900DFQ38463745-ACB91202-08C1-4A62-8F37-3C1E80D83353
P2860
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@ast
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@en
type
label
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@ast
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@en
prefLabel
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@ast
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@en
P2093
P2860
P1433
P1476
Cardiovascular outcomes and mo ...... ion or acute coronary syndrome
@en
P2093
Jeremy A Rassen
Jerry Avorn
Niteesh K Choudhry
Sebastian Schneeweiss
P2860
P304
P356
10.1161/CIRCULATIONAHA.109.873497
P407
P577
2009-11-23T00:00:00Z